building value in the public-private crossover fund, ARK Ventures (current symbol ARKVX), and on the public funds: especially across the Multiomics and AI strategies. Under his leadership of the Venture team, assets under management on the private side were built to over $1B overall, in under three years since the inception of privates. Charles joined ARK full time in 2023.
Prior to ARK, Charles's background was as a deep tech entrepreneur and serial founder with a focus on AI convergences. He has been a cofounder at a number of companies including Freenome, a unicorn of ~400 people working on saving lives through earlier cancer detection. Freenome completed one of the world's largest ever clinical registrational studies in ~50,000 subjects and submitted PMA to FDA, having raised ~$1.4B from leading investors including Roche, Fidelity, Janus, T.Rowe Price, and VCs including a16z, GV and DCVC. Freenome recently announced a distribution deal of up to $885M with Exact Sciences. He cofounded other AI/tech-bio companies including (as Chair) Relation, also backed by DCVC co-led with NVIDIA, plus Deerfield and other strategic investors including GSK. Relation has raised over $100M, and announced a deal with GSK for up to $200M per target. Charles also cofounded biotechs Agalimmune (acquired by a Nasdaq-listed company) and Centauri Tx, backed by Novo and Boerhinger Ingelheim, cofounded with the Nobel Laureate inventor of PCR. Charles also cofounded a non-invasive prenatal testing company that brought the first CE-marked NIPT test using NGS to market and conducted testing for more than 2 million patients. Charles previously served as advisor to OSE, Oxford University’s ~$1B spin-out fund, and ran a venture studio family office.
Charles holds four degree-level qualifications, having graduated with degrees in Psychology (BSc., University College London, 2001), in Medicine (University of Dundee, 2002), MR
This speaker willtalk about
Find here the list of all the sessions presented by this speaker in order not to miss any of it.
